Clinical Trial Update: CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CART-BCMA/CS1 for relapsed or refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CART-BCMA/CS1

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: WITHDRAWN